# Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

> **NCT06783790** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- AML (Acute Myelogenous Leukemia)

## Interventions

- **DRUG:** Avapritinib, azacitidine, Venetoclax

## Key facts

- **NCT ID:** NCT06783790
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06783790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06783790, "Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06783790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*